ALTHOUGH no Cebu-based graduates made it to the top 10 of the November 2020 Physician Licensure Examinations (PLE), the Professional Regulatory Commission (PRC) named a Cebu-based medicine school as the top 1 among the top performing schools this year.
The Cebu Institute of Medicine (CIM) ranked first among the top ten performing schools in the November 2020 PLE after all of its 138 first time-takers have passed the examinations, giving the school a 100 percent passing rate.
The CIM was followed by the University of the Philippines (UP)-Manila with 98.63 percent passing rate and Ateneo School of Medicine and Public Health with 98.60 percent.
The PRC released the results of the November 2020 PLE on Thursday, November 26, 2020 or seven working days after the last day of the examination.
The PRC said a total of 3,538 out of the 4,704 takers passed this year’s PLE administered by the Board of Medicine in the Cities of Manila, Baguio, Cagayan de Oro, Cebu, Davao, Iloilo, Legazpi, Lucena, Tacloban, Tuguegarao and Zamboanga.
A UP-Manila graduate, Jomel Lapides, emerged as the top 1 with a rate of 88.67 percent, followed by Patrick Joseph Mabugat from University of Saint La Salle and Adrian Teves from University of Sto. Tomas (UST) who both garnered 88.58 percent while both Henrick Fong of UST and Raphael Rodolfo of UP-Manila ranked third with a rate of 88.33 percent. (WBS)
Oct. 27 (UPI) — Google is celebrating Bulgarian physician and microbiologist Dr. Stamen Grigorov with a new Doodle Tuesday, on what would have been his 142nd birthday.
Grigorov, who was born in 1878 in the village of Studen Izvor in the Trun region of Bulgaria, is the first scientist to discover the bacterium essential to the fermentation of yogurt. He also helped with the development of the first tuberculosis vaccine.
Google’s homepage features artwork of Grigorov being surrounded by multiple bowls of yogurt.
Grigorov, who worked as a research assistant at the Medical University of Geneva, Switzerland, started to inspect yogurt under a microscope after being intrigued by its reported health benefits.
The scientist found the rod-shaped microorganism that causes yogurt’s fermentation in 1905 after thousands of experiments. The bacterium was named Lactobacillus bulgaricus, in honor of his home nation of Bulgaria.
The following year, Grigorov released a groundbreaking paper demonstrating the first use of penicillin fungi against tuberculosis while working as chief physician at a hospital in Trun.
Studen Izvor is home to the world’s only yogurt museums.
Healthcare Consultants Urge Hospitals and Health Systems to Start Planning for Impact on Physician Compensation and Medicare Payments for Professional Services.
Neal D. Barker, Partner at HSG, a national healthcare consulting firm is the author of “Changes to the 2021 Medicare Physician Fee Schedule Could Have Major Impact on Physician Compensation.” The article is available for download at the website, hsgadvisors.com.
Louisville, KY, Oct. 21, 2020 (GLOBE NEWSWIRE) — HSG, a national healthcare consulting firm, has published a detailed evaluation of the Centers for Medicare & Medicaid Services (CMS) 2021 Medicare Physician Fee Schedule (MPFS) Proposed Rule, which is scheduled to take effect on January 1, 2021, if approved in the Final Rule. The advisors at HSG believe the proposed changes may have a significant potential impact on physician compensation and urge healthcare executives to start planning for these proposed changes. The agency’s Fee Schedule changes cover everything from Work Relative Value Unit (wRVU) values for specific Current Procedural Terminology (CPT) codes to changes in the scope of practice policies for Advanced Practice Providers (APPs) and changes related to CMS’s quality payment program.
With more than a 10% decrease in the MPFS conversion factor, services that do not have any change in Relative Value Unit values will see a decrease in Medicare payment at the projected rate of more than 10%. The decreased reimbursement will not be fully offset by any reimbursement increases realized through the Quality Payment Program paths. Changes related to outpatient and office evaluation and management (E&M) service code determinations and requirements, along with permanent and temporary additions to telehealth codes, will add to compensation complications. The redefined E&M code selection criteria will now be driven by medical decision making (MDM) or time spent alone – with no direct contribution by history and/or exam elements.
“Assuming these changes are included when the Final Rule is published in early December, many industry organizations, consultancies, and provider advocacy groups are projecting significant increases in provider productivity-based compensationif the providers’ E&M profile remains unchanged,” explained Neal Barker, Partner at HSG. “Ultimately, hospitals and health systems may face a situation in which payments from Medicare will decrease while their physician compensation requirements will significantly increase based on the widespread use of wRVU-based compensation models for employed physicians and APPs.”
As the roll-out date for the new Fee Schedule grows closer, HSG is working with healthcare systems to help them gain an understanding of the potential impact on the network. Then HSG works with the organization to build a model to address changes to wRVU targets and bonus conversion factors that yield productive compensation levels that are financially sustainable and uphold fair market value and commercial reasonableness. Coincident with the compensation impact review, HSG conducts a series of provider
Over the past decade, we witnessed unprecedented advances in the field of biogerontology, and the massive convergence of biotechnology, information technology, AI, and medicine. And now we are witnessing the birth of a new field of longevity medicine, which integrates the latest advances in many of these fields of science and technology. My definition longevity medicine is advanced personalized preventative medicine powered by deep biomarkers of aging and longevity.
And, like in the field of AI for drug discovery, women are at the forefront of this revolution and there were precedents when we had to look for a male physician to make a conference panel more diverse.
One of the physician-scientists who stands out in this area is Dr. Evelyne Yehudit Bischof. I first got a note with a request for more information on one of our research papers from Dr. Bischof on December 30th, 2019 while in Shanghai. A request I almost ignored due to the heavy workload but accidentally I looked at her profile which was highly unusual. In brief, Evelyne is a German medical doctor with an MD from Max Planck Institute for Molecular Biology and Genetics, who interned at Columbia University, and Harvard MGH and Beth Israel Medical Deaconess, attending physician at University Hospital Basel in Switzerland, and associate professor at Shanghai University of Medicine and Health Sciences. She fluently spoke six languages including German, Russian, and Mandarin Chinese, which was quite impressive. The second time we met was at Human Longevity Inc, in San Diego when she was interviewing with one of the most influential entrepreneurs and investors in longevity biotechnology, Dr. Wei-Wu He to join HLI as a longevity physician.
The longevity industry is rapidly emerging and longevity clinics are being set up in various parts of the world. So I decided to ask Eva a few questions to elucidate this new and emerging industry.
Alex: Eva, we know each other for almost a year and you do not fail to impress with your academic publications, public lectures, and clinical work. You are as close to the “longevity physician” as it can possibly get. Can you tell us a bit more about yourself and about the work that you are doing on the clinical side and on the research side?
Dr. Evelyne Bischof: Thank you, Alex – it is an honor to be so generously introduced by a true innovator, scientist and entrepreneur, as well as a longevity KOL and allow me to revert the compliment. I am a rather globally oriented internal medicine specialist, with training and work experience in Germany, USA, Switzerland and China. For almost a decade now, I have been splitting my time between Shanghai and Basel, creating a path that allowed me to conclude my residency and fellowship, develop translational and clinical research niches and collaborators, as well as to engage actively in academic medical education. While